The US Food and Drug Administration (FDA) has published a report on its progress in the generic drug development space during 2019.
In order to assist the drugmakers behind these affordable medicines, the Generic Drug User Fee Amendments of 2012 (GDUFA) established a formal regulatory science program and funded research activities for investigating new methodologies and tools for their development.
The GDUFA was reauthorized in 2017 through 2022 under the name GDUFA II. The latest report elaborates on the results of these efforts in 2019, which marks the second year of GDUFA II.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze